PSTX
POSEIDA THERAPEUTICS INC
1 day chart
About PSTX
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which utilizes its genetic engineering platform technologies to create cell and gene therapeutics. The Company's platforms include ournon-viral piggyBac DNA Delivery System, Cas-CLOVER Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Its advanced product candidate, P-PSMA-101, is being developed for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC), in a Phase I trial. Its first two fully allogeneic CAR-T product candidates include P-BCMA-ALLO1 and P-MUC1C-ALLO1, both are in Phase I trial. P-BCMA-ALLO1 is developed for patients with relapsed/refractory multiple myeloma. P-MUC1C-ALLO1 is being developed to treat a range of solid tumors, including breast, ovarian and other epithelial-derived cancers. In addition, the Company has several additional allogeneic programs advancing toward anticipated IND filings, including P-CD19CD20-ALLO1.
Buy US stocks in Australia starting with PSTX. Open an account and start investing today!
$269.96M
-
0.00%
101.22K
$3.24
$3.09
$3.14
$8.82
$1.82
PSTX FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in PSTX
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.